MP14-19 A NOVEL ANTI-EPOR CAR-T CELL FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA
Jingcheng Zhou,Jing Cui,Haibiao Xie,Kaifang Ma,Lei Li,Kenan Zhang,Zhengping Zhuang,Kan Gong,Lin Cai
DOI: https://doi.org/10.1097/ju.0000000000000839.019
2020-01-01
Abstract:You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Apr 2020MP14-19 A NOVEL ANTI-EPOR CAR-T CELL FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA Jingcheng Zhou*, Haibiao Xie, Kaifang Ma, Lei Li, Kenan Zhang, Kan Gong, and Lin Cai Jingcheng Zhou*Jingcheng Zhou* More articles by this author , Haibiao XieHaibiao Xie More articles by this author , Kaifang MaKaifang Ma More articles by this author , Lei LiLei Li More articles by this author , Kenan ZhangKenan Zhang More articles by this author , Kan GongKan Gong More articles by this author , and Lin CaiLin Cai More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000839.019AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Chimeric antigen receptor (CAR) T cell is a promising treatment approach for renal cell carcinoma (RCC) but has been limited by the specificity of antigens. Here, we demonstrate that erythropoietin receptor (EPOR) is a tumor-associated antigen highly expressed in RCC. We developed a novel anti-EPOR CAR-T cell consisting of scFv against EPOR which demonstrates good efficacy in vitro and in vivo. METHODS: First, we illustrated the expression of EPOR in patient derived RCC tumor specimens, as well as various renal cell cancer cell lines. Then, we constructed the EPOR antigen and immunize mice to obtain monoclonal antibody from hybridoma cells. Validated monoclonal cell line with the strongest RCC cell killing ability was performed 5’RACE sequencing to get the scFv sequence, which was subsequently combined with 3rd generation CAR vector. CAR-T cells were generated against EPOR and efficacy was evaluated in RCC cell lines under normoxia, hypoxia and EPO stimulated condition. Cytotoxicity was determined via LDH, IFN-γ, TNF-α, and IL-2 levels released from tumor cells killed by anti-EPOR CAR-T cells. Finally, we evaluated the in vivo therapeutic effect with intravenous injection on xenograft mouse model using 786-0 cell line. RESULTS: EPOR was highly expressed in RCC cell lines and patient tumor samples. We demonstrated that anti-EPOR monoclonal antibodies and CAR-T cells have the ability to kill RCC cells in vitro. While the xenograft tumor volume in anti-EPOR CAR-T group being significantly suppressed after intravenous injection 2 weeks in vivo, the mice shown side effects (e.g., pulmonary consolidation, congestive hepatomegaly) probably due to the EPOR expression in specific organs. CONCLUSIONS: We developed a type of novel CAR-T cells targeting EPOR which shown cytotoxicity against RCC cells in vitro and in vivo. This data indicates that anti-EPOR CAR-T is promising to be a therapeutic target. However, considering the side effects, new CAR-T strategies should be used to optimize it in the future. Source of Funding: This work was supported by the National Natural Science Foundation of China (grant 81572506 and grant 81872081), the Fundamental Research Funds for the Central Universities (grant BMU2018JI002) and the NCI Intramural Research Program. The first author acknowledges a scholarship (201806010388) funded by the China Scholarship Council. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e203-e203 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jingcheng Zhou* More articles by this author Haibiao Xie More articles by this author Kaifang Ma More articles by this author Lei Li More articles by this author Kenan Zhang More articles by this author Kan Gong More articles by this author Lin Cai More articles by this author Expand All Advertisement PDF downloadLoading ...